Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain

European Journal of Human Genetics

Volumn 17, Issue 8, 2009, Pages 991-998

  Gurwitz, David ^a   Rodríguez Antona, Cristina ^b   Payne, Katherine ^c   Newman, William ^c   Gisbert, Javier P ^d   de Mesa, Emma Gutiérrez ^e   Ibarreta, Dolores ^e  

^a TEL AVIV UNIVERSITY   (Israel)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e JOINT RESEARCH CENTRE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; THIOPURINE METHYLTRANSFERASE; THIOPURINE METHYLTRANSFERASE 2; THIOPURINE METHYLTRANSFERASE 3A; THIOPURINE METHYLTRANSFERASE 3C; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; APLASTIC ANEMIA; ARTICLE; BONE MARROW DEPRESSION; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; COST EFFECTIVENESS ANALYSIS; DRUG FATALITY; DRUG SURVEILLANCE PROGRAM; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; ETHNIC DIFFERENCE; EUROPE; FEBRILE NEUTROPENIA; GENE FREQUENCY; GENE FUNCTION; GENETIC VARIABILITY; GENOTYPE; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; LIVER FAILURE; MAJOR CLINICAL STUDY; PANCYTOPENIA; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SEPSIS; SPAIN; THROMBOCYTOPENIA; UNITED KINGDOM;

AZATHIOPRINE; COST-BENEFIT ANALYSIS; DRUG MONITORING; EUROPE; FOLLOW-UP STUDIES; GENETIC SCREENING; GENOTYPE; GREAT BRITAIN; HUMANS; METHYLTRANSFERASES; MODELS, BIOLOGICAL; PHARMACOGENETICS; PHENOTYPE; SPAIN;

EID: 67749132476     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2009.10     Document Type: Article

References (41)

1. Teml A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M: Thiopurine treatment in inflammatory bowel disease: Clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet 2007; 46: 187-208.
2. Coulthard SA Hogarth L: The thiopurines: an update. Invest New Drugs 2005; 23: 523-532.
3. Dubinsky MC: Azathioprine, 6-mercaptopurine in inflammatory bowel disease: Pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol 2004; 2: 731-743.
4. Timmer A, McDonald JW, Macdonald JK: Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007: CD000478.
5. Massacesi L, Parigi A, Barilaro A et al: Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging. Arch Neurol 2005; 62: 1843-1847.
6. Patel AA, Swerlick RA, TcCall CO: Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol 2006; 55: 369-389.
7. Wang L, Weinshilboum R: Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 2006; 25 1629-1638.
8. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE: Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34: 1081-1085.
9. Clunie GP, Lennard L: Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine. Rheumatology (Oxford) 2004; 43: 13-18.
10. Gisbert JP, Luna M, Gonzalez-Lama Y et al: Liver injury in inflammatory bowel disease: Long-term follow-up study of 786 patients. Inflamm Bowel Dis 2007; 13: 1106-1114.
11. Shaye OA, Yadegari M, Abreu MT et al: Hepatotoxicity of 6-mercaptopurine (6-MP) and azathioprine (AZA) in adult IBD patients. Am J Gastroenterol 2007; 102: 2488-2494.
12. Zelinkova Z, Derijks LJ, Stokkers PC et al: Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin Gastroenterol Hepatol 2006; 4: 44-49.
13. Baker DE: Pharmacogenomics of azathioprine and 6-mercaptopurine in gastroenterologic therapy. Rev Gastroenterol Disord 2003; 3: 150-157.
14. Gearry RB, Barclay ML: Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol 2005; 20: 1149-1157.
15. Boonsrirat U, Angsuthum S, Vannaprasaht S et al: Azathioprine-induced fatal myelosuppression in systemic lupus erythematosus patient carrying TPMT*3C polymorphism. Lupus 2008; 17: 132-134.
16. Weinshilboum RM, Sladek SL:MMercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651-662.
17. Engen RM, Marsh S, Van Booven DJ, McLeod HL: Ethnic differences in pharmacogenetically relevant genes. Curr Drug Targets 2006; 7 1641-1648.
18. Jones TS, Yang W, Evans WE, Relling MV: Using HapMap tools in pharmacogenomic discovery: The thiopurine methyltransferase polymorphism. Clin Pharmacol Ther 2007; 81: 729-734.
19. Kham SK, Soh CK, Liu TC et al: Thiopurine S methyltransferase activity in three major Asian populations: A population-based study in Singapore. Eur J Clin Pharmacol 2008; 64: 373-379.
20. van den Akker-van Marle ME, Gurwitz D, Detmar SB et al: Cost-effectiveness of pharmacogenomics in clinical practice: A case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics 2006; 7: 783-792.
21. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI: 6-Mercaptopurine in the management of inflammatory bowel disease: Short- and long-term toxicity. Ann Intern Med 1989; 111: 641-649.
22. Hazell L, Shakir SA: Under-reporting Af adverse drug reactions: a systematic review. Drug Saf 2006; 29: 385-396.
23. Payne K: Towards an economic evidence base for pharmacogenetics: consideration of outcomes is key. Pharmacogenomics 2008; 9: 1-4.
24. Gisbert JP, Gomollon F, Cara C et al: Thiopurine methyltransferase activity in Spain: A study of 14 545 patients. Dig Dis Sci 2007; 52: 1262-1269.
25. Gisbert JP, Luna M, Mate J, Gonzalez-Guijarro L, Cara C, Pajares JM: Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study. Hepatogastroenterology 2006; 53: 399-404.
26. Kroplin T, Weyer N, Gutsche S, Iven H: Thiopurine S methyltransferase activity in human erythrocytes: A new HPLC method using 6-thioguanine as substrate. Eur J Clin Pharmacol 1998; 54 265-271.
27. Ford L, Prout C, Gaffney D, Berg J: Whose TPMT activity is it anyway? Ann Clin Biochem 2004; 41: 498-500.
28. Holme SA, Duley JA, Sanderson J et al: Erythrocyte thiopurine methyl transferase assessment prior to AZA use in the UK. QJM 2002; 95: 439-444.
29. Fargher EA, Tricker K, Newman W et al: Current use of pharmacogenetic testing: A national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J Clin Pharm Ther 2007; 32: 187-195.
30. Ansari A, Hassan C, Duley J et al: Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 1743-1750.
31. Oliveira E, Quental S, Alves S, Amorim A, Prata MJ: Do the distribution patterns of polymorphisms at the thiopurine S-methyltransferase locus in sub-Saharan populations need revision? Hints from Cabinda and Mozambique. Eur J Clin Pharmacol 2007; 63: 703-706.
32. Cooper SC, Ford LT, Berg JD, Lewis MJ: Ethnic variation of thiopurine S-methyltransferase activity: A large, prospective population study. Pharmacogenomics 2008; 9: 303-309.
33. Stocco G, Martelossi S, Barabino A et al: Glutathione-S transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 57-64.
34. Ansari A, Arenas M, Greenfield S et al: Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008; 28: 973-983.
35. Stocco G, Cheok M, Crews K et al: Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther 2009; 85: 164-172.
36. Hogarth LA, Redfern CP, Teodoridis JM et al: The effect of thiopurine drugs on DNA methylation in relation to TPMT expression. Biochem Pharmacol 2008; 76: 1024-1035.
37. Payne K, Newman W, Fargher E et al: TPMT testing in rheumatology: any better than routine monitoring? Rheumatology (Oxford) 2007; 46: 727-729.
38. Wadelius M, Pirmohamed MC Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 2007; 7: 99-111.
39. Payne K, Newman WG, Gurwitz D, Ibarreta D, Phillips KA: TPMT testing in azathioprine: A 'cost-effective use of healthcare resources'?. Personalized Med 2009; 6: 103-113.
40. McLaughlin MJ: HTE Policy Roundtable Panel. Healthcare policy implications of heterogeneity of treatment effects. Am J Med 2007; 120 (4 Suppl 1): S32-S35.
41. Department of Health and Human (HHS) Services Secretary's Advisory CoRmittee on Genetics, Health, and Society (SACGHS): Report: realizing the potential of pharmacogenomics: Opportunities and challenges (May 2008). http://oba.od.nih.gov/oba/SACGHS/reports/SACGHS_PGx_report.pdf.